Incyte reports Q2 EPS $1.57, consensus $1.48

Reports Q2 revenue $1.22B, consensus $1.15B. “As I begin my tenure as CEO, I look forward to leading Incyte (INCY) through its next phase of growth and value creation for patients, partners and shareholders. Our second quarter results reflect strong growth for Jakafi, Opzelura cream and Niktimvo, positioning us well to deliver on our 2025 objectives,” said Bill Meury, CEO, Incyte. “During the quarter, we achieved two regulatory milestones with the approvals of Zynyz for squamous cell anal carcinoma and Monjuvi for follicular lymphoma, further expanding our ability to address patients’ needs. Continued progress and diversification of our portfolio, including advancements with povorcitinib and mutCALR, are strengthening the foundation for sustainable, long-term growth.”